IGC Pharma在AI平台MINT-AD揭幕,提前预测阿尔茨海默氏病的风险年份。 IGC Pharma unveils AI platform MINT-AD, predicting Alzheimer's risk years in advance.

IGC Pharma开发了MINT-AD,这是一个AI平台,通过分析脑扫描、遗传学、生活方式和认知度量来预测阿尔茨海默氏症在出现症状之前的几年的风险。 IGC Pharma has developed MINT-AD, an AI platform that predicts Alzheimer's risk years before symptoms appear by analyzing brain scans, genetics, lifestyle, and cognitive metrics. 该平台旨在加强早期发现和个性化护理,有可能融入一般做法和服务不足的地区。 The platform aims to enhance early detection and personalized care, potentially integrating into general practices and underserved areas. 将在2026财政年度推出一个贝塔版本,与学术和临床伙伴一起进行评估。 A beta version is set to launch in Fiscal 2026 for evaluation with academic and clinical partners.